Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 5 studies | 27% ± 5% | |
abnormal cell | 4 studies | 30% ± 14% | |
epithelial cell | 4 studies | 33% ± 18% | |
pericyte | 4 studies | 20% ± 6% | |
retinal ganglion cell | 3 studies | 70% ± 18% | |
goblet cell | 3 studies | 28% ± 14% | |
glutamatergic neuron | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
eye | 3 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 5006.28 | 245 / 245 | 100% | 48.95 | 502 / 502 |
adrenal gland | 100% | 4686.89 | 258 / 258 | 99% | 68.26 | 228 / 230 |
pancreas | 100% | 2109.78 | 328 / 328 | 98% | 35.58 | 174 / 178 |
uterus | 99% | 2025.48 | 169 / 170 | 98% | 32.89 | 451 / 459 |
breast | 100% | 2472.68 | 458 / 459 | 97% | 32.57 | 1090 / 1118 |
thymus | 100% | 2686.54 | 653 / 653 | 97% | 29.74 | 588 / 605 |
lung | 99% | 2084.08 | 575 / 578 | 97% | 35.38 | 1125 / 1155 |
brain | 99% | 1587.73 | 2624 / 2642 | 97% | 21.55 | 685 / 705 |
skin | 100% | 3614.55 | 1809 / 1809 | 96% | 29.93 | 453 / 472 |
intestine | 100% | 1920.05 | 962 / 966 | 96% | 21.80 | 506 / 527 |
bladder | 100% | 2749.57 | 21 / 21 | 95% | 29.84 | 481 / 504 |
esophagus | 100% | 3152.40 | 1445 / 1445 | 95% | 18.87 | 173 / 183 |
kidney | 99% | 1918.78 | 88 / 89 | 95% | 82.50 | 855 / 901 |
stomach | 99% | 1608.86 | 357 / 359 | 81% | 16.13 | 233 / 286 |
liver | 96% | 1757.61 | 218 / 226 | 82% | 21.04 | 334 / 406 |
ovary | 100% | 2018.66 | 180 / 180 | 73% | 10.47 | 314 / 430 |
adipose | 100% | 2235.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 4859.23 | 803 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2580.84 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 3412.51 | 843 / 861 | 0% | 0 | 0 / 0 |
spleen | 98% | 1032.97 | 235 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 30.00 | 78 / 80 |
tonsil | 0% | 0 | 0 / 0 | 96% | 22.15 | 43 / 45 |
lymph node | 0% | 0 | 0 / 0 | 31% | 2.94 | 9 / 29 |
peripheral blood | 21% | 254.21 | 194 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0062099 | Biological process | negative regulation of programmed necrotic cell death |
GO_0014876 | Biological process | response to injury involved in regulation of muscle adaptation |
GO_1901222 | Biological process | regulation of non-canonical NF-kappaB signal transduction |
GO_0006376 | Biological process | mRNA splice site recognition |
GO_0001974 | Biological process | blood vessel remodeling |
GO_0002931 | Biological process | response to ischemia |
GO_0090201 | Biological process | negative regulation of release of cytochrome c from mitochondria |
GO_1902176 | Biological process | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway |
GO_0014736 | Biological process | negative regulation of muscle atrophy |
GO_0051259 | Biological process | protein complex oligomerization |
GO_0097193 | Biological process | intrinsic apoptotic signaling pathway |
GO_0008380 | Biological process | RNA splicing |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0001666 | Biological process | response to hypoxia |
GO_0010659 | Biological process | cardiac muscle cell apoptotic process |
GO_2001237 | Biological process | negative regulation of extrinsic apoptotic signaling pathway |
GO_1902109 | Biological process | negative regulation of mitochondrial membrane permeability involved in apoptotic process |
GO_0010667 | Biological process | negative regulation of cardiac muscle cell apoptotic process |
GO_2001243 | Biological process | negative regulation of intrinsic apoptotic signaling pathway |
GO_0014808 | Biological process | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum |
GO_1990001 | Biological process | inhibition of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_1903298 | Biological process | negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway |
GO_0005730 | Cellular component | nucleolus |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005829 | Cellular component | cytosol |
GO_0016529 | Cellular component | sarcoplasmic reticulum |
GO_0043027 | Molecular function | cysteine-type endopeptidase inhibitor activity involved in apoptotic process |
GO_0042802 | Molecular function | identical protein binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005123 | Molecular function | death receptor binding |
GO_0089720 | Molecular function | caspase binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0035877 | Molecular function | death effector domain binding |
Gene name | NOL3 |
Protein name | Nucleolar protein 3 (Apoptosis repressor with CARD domain) (cDNA, FLJ95803, Homo sapiens nucleolar protein 3 (apoptosis repressor with CARD domain) (NOL3), mRNA) Nucleolar protein 3 Nucleolar protein 3 (Apoptosis repressor with CARD) (Muscle-enriched cytoplasmic protein) (Myp) (Nucleolar protein of 30 kDa) (Nop30) |
Synonyms | ARC NOP hCG_28817 |
Description | FUNCTION: [Isoform 1]: May be involved in RNA splicing. .; FUNCTION: [Isoform 2]: Functions as an apoptosis repressor that blocks multiple modes of cell death. Inhibits extrinsic apoptotic pathways through two different ways. Firstly by interacting with FAS and FADD upon FAS activation blocking death-inducing signaling complex (DISC) assembly (By similarity). Secondly by interacting with CASP8 in a mitochondria localization- and phosphorylation-dependent manner, limiting the amount of soluble CASP8 available for DISC-mediated activation (By similarity). Inhibits intrinsic apoptotic pathway in response to a wide range of stresses, through its interaction with BAX resulting in BAX inactivation, preventing mitochondrial dysfunction and release of pro-apoptotic factors . Inhibits calcium-mediated cell death by functioning as a cytosolic calcium buffer, dissociating its interaction with CASP8 and maintaining calcium homeostasis . Negatively regulates oxidative stress-induced apoptosis by phosphorylation-dependent suppression of the mitochondria-mediated intrinsic pathway, by blocking CASP2 activation and BAX translocation (By similarity). Negatively regulates hypoxia-induced apoptosis in part by inhibiting the release of cytochrome c from mitochondria in a caspase-independent manner (By similarity). Also inhibits TNF-induced necrosis by preventing TNF-signaling pathway through TNFRSF1A interaction abrogating the recruitment of RIPK1 to complex I (By similarity). Finally through its role as apoptosis repressor, promotes vascular remodeling through inhibition of apoptosis and stimulation of proliferation, in response to hypoxia (By similarity). Inhibits too myoblast differentiation through caspase inhibition (By similarity). . |
Accessions | ENST00000564992.2 [O60936-2] O60936 ENST00000568146.1 [O60936-1] H3BM67 ENST00000564860.1 ENST00000564053.5 [O60936-2] H3BUN4 ENST00000564992.2 J3QLT7 H3BQJ5 ENST00000563258.1 H3BUP2 ENST00000563439.5 ENST00000565560.5 Q5TZN6 ENST00000566871.5 J3QLS5 |